Management of inherited thrombophilia in pregnancy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 6, 2009, Pages 464-469

  Fogerty, Annemarie E ^a   Connors, Jean M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Inherited thrombophilia; Pregnancy; Venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CYANOCOBALAMIN; DALTEPARIN; ENOXAPARIN; FOLIC ACID; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN; PYRIDOXINE; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BLOOD FLOW VELOCITY; CASE CONTROL STUDY; CIRCADIAN RHYTHM; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; GENE MUTATION; GENETIC POLYMORPHISM; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HETEROZYGOSITY; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; OSTEOPOROSIS; POINT MUTATION; POPULATION; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANT WOMAN; PREVALENCE; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUERPERIUM; RETROSPECTIVE STUDY; REVIEW; RISK; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 70350761744     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328332b81e     Document Type: Review

References (38)

1. De Stefano V, Rossi E, Za T, et al. Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. Semin Throm Haemost 2006; 32:767-780.
2. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353:1258-1265.
3. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year populationbased study. Ann Intern Med 2005; 143:697-706.
4. James AH, Jamison MG, Brancazio LR, Myers MR. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194:1311-1315.
5. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: A meta-analysis of the period of risk and leg of presentation. Obstet Gynecol Surv 1999; 54:265-271.
6. Simpson EL, Lawrenson RA, Nightingale AL, et al. Venous thromboembolism in pregnancy and the puerperium: Incidence and additional risk factors from a London perinatal database. BJOG 2001; 108:56-60.
7. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol 2005; 193:216-219.
8. The National Institute for Clinical Excellence. Why mothers die 2000- 2002: Report on confidential enquiries into maternal deaths in the United Kingdom. London: Royal College of Obstetricians and Gynaecologists Press; 2003.
9. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers' lives: Reviewing maternal deaths to make motherhood safer - 2003-2005: The seventh report on confidential enquires into maternal deaths in the United Kingdom. London: CEMACH; 2007.
10. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29:125-130.
11. Lockwood C. Pregnancy-associated changes in the hemostatic system. Clin Obstet Gynecol 2006; 49:836-843.
12. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
13. Walker ID. Congenital thrombophilia. Baillieres Clin Obstet Gynaecol 1997; 11:431-445.
14. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening. JAMA 1997; 277:1305-1307.
15. Zheng H, Tzeng CC, Butt C, et al. An extremely low prevalence of FVL, FIIG20210A and FXIIIV34L in Taiwan Chinese population. Thromb Haemost 2002; 87:1081-1082.
16. Diley A, Austin H, Hooper WC, et al. Prevalence of the prothrombin 20210 Gto- A variant in blacks: Infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998; 132:452-455.
17. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79:706-708.
18. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Int Med 1998; 128:15-20.
19. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202.
20. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: A systematic review. Br J Haematol 2006; 132:171-196.
21. Bank I, Linourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164:1932-1937.
22. Lijfering WM, Brouwer JL, Veeger MJCM, et al. Selective testing for thrombophilia in patients with first venous thrombosis: Results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113:5314-5322.
23. den Heijer M, Willems HPJ, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 199:139-144.
24. Ray JG, Kearon CK, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism. Ann Intern Med 2007; 146:761-767.
25. Folsom AR, Cushman M, Heckbert SR, et al. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003; 56:598-603.
26. van der Bom JG, Bots ML, Haverkate F, et al. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003; 101:1841-1844.
27. Coppens M, Kaandorp SP, Middeldorp S. Inherited thrombophilias. Obstet Gynecol Clin North Am 2006; 33:357-374.
28. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322-327.
29. Coppens M, Van de Poel MH, Hamulyak K, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108:2604-2607.
30. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of deficiency of antithrombin, protein C, or protein S: A prospective cohort study. Blood 1999; 94:3702-3706.
31. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350:1914-1915.
32. Mazzolai L, Hohlfeld P, Spertini F, et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108:1569-1570.
33. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl):844S-886S.
34. Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: Consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197:457.e1-457.e21.
35. Brouwer JP, Lijfering WM, ten Kate MK, et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101:93-99.
36. Dargaud Y, Rugeri L, Vergnes MC, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: A multicentre prospective study. Br J Haematol 2009; 145:825-835. assigned risk score.
37. Brill-Edwards R, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343:1439-1444.
38. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005; 106:401-407.